News | Artificial Intelligence | June 24, 2020

VUNO Receives CE Mark for 5 Medical AI Solutions

Medical artificial intelligence (AI) solution development company VUNO gained the Class IIa CE markings for five of their AI solutions.

June 24, 2020 — Medical artificial intelligence (AI) solution development company VUNO gained the Class IIa CE markings for five of their AI solutions.

The five CE marked solutions are: VUNO Med-BoneAge, VUNO Med-DeepBrain, VUNO Med-Chest X-Ray, VUNO Med–Fundus AI and VUNO Med–LungCT AI. These products can now be commercialized and sold in 27 member states of the European Union, the Acceding countries as well as EFTA states. They can also make inroads into countries that recognize the European CE mark such as those in the Middle East, Asia, South and Central America, and Africa.

VUNO was assessed and deemed to meet EU safety and health protection requirements by a Notified Body based on a more stringent clinical validation standards and medical device guidelines. The efficacy and safety of those products demonstrated by a series of clinical research results and papers published in high impact journals and prestigious international seminars were of great help to satisfy the strict requirements.

Of the five MFDS (Ministry of Food and Drug Safety) approved products, four products (VUNO Med-Fundus AI, VUNO Med-Chest X-ray, and VUNO Med - BoneAge and VUNO Med Lung CT AI) received regulatory approval based on the proven effectiveness of performance through clinical trials. With such a robust portfolio, it is anticipated that VUNO Med solutions are to be used as key diagnostic supporting tools across many different medical environments overseas.

Hyun-Jun Kim, CEO of VUNO explained that, "We have been taking proper measures to ensure that VUNO's products obtain classification commensurate with their intended purposes as medical diagnostic supporting tools". He also added that, "In this sense, obtaining CE certification for all five products holds a great significance, and this will be able to accelerate our push for much anticipated global supply of VUNO Med series all around the world."

VUNO has been graining great traction at home and abroad with more than 100 active users of hospitals in Korea alone and is ready to deploy the CE marked products to international business partners and clients across different markets.

For more information: www.vuno.co

Related Content

Of all the buzzwords one would have guessed would dominate 2020, few expected it to be “virtual”. We have been virtualizing various aspects of our lives for many years, but the circumstances of this one has moved almost all of our lives into the virtual realm.

Getty Images

Feature | Radiology Education | September 18, 2020 | By Jef Williams
Of all the buzzwords one would have guessed would dominate 2020, few expected it to be “virtual”.
Indeterminate lesion on PET/CT classified by PET/MRI for 53-y-old man with lung cancer.

Indeterminate lesion on PET/CT classified by PET/MRI for 53-y-old man with lung cancer. Contrast-enhanced CT (A), PET (B), and fused 18F-FDG PET/CT (C) images are displayed in comparison with contrast-enhanced T1-weighted MRI (D), PET, and fused 18F-FDG PET/MRI (F) images. In CT (A), hyperdense, subcentimeter liver lesion (arrows) in segment VII is suggestive of transient hepatic attenuation difference or small hemangioma. As malignancy cannot be excluded, it needs further investigation. On PET/MRI, lesion is clearly classified as metastasis because of contrast enhancement and tracer uptake due to later acquisition time point. Follow-up CT confirmed diagnosis after 78 d. Images created by Ole Martin, University Dusseldorf, Medical Faculty and Benedikt Schaarschmidt, University Hospital Essen.

News | PET-MRI | September 18, 2020
September 18, 2020 — A single-center observational study of more than 1,000 oncological examinations has demonstrated
The COVID-19 pandemic has impacted every facet of personal life, business operations and healthcare, including breast imaging and breast cancer care.

Getty Images

Feature | Breast Imaging | September 18, 2020 | By Susan Harvey, M.D.
The COVID-19 pandemic has impacted every facet o
As the silos of data and diagnostic imaging PACS systems are being collapsed and secured, the modular enterprise imaging platform approach is gaining significance, offering systemness and security
Feature | Coronavirus (COVID-19) | September 18, 2020 | By Anjum M. Ahmed, M.D., MBBS, MBA, MIS
COVID-19 is now everywhere, and these are the lo
Cloud and cloud-native architecture is the future for computing solutions in EI applications

Getty Images

Feature | Enterprise Imaging | September 18, 2020 | By Henri “Rik” Premo
With over five years of presence in the rapidly expanding...
Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries

Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries 

Feature | Radiology Imaging | September 17, 2020 | By Robert Bard, M.D. PC, DABR, FASLM
COVID-19 is routinely studied using...
Ultrasound-guided carpal tunnel release quickly improves hand function and reduces hand discomfort, making the procedure a safe, effective, and less invasive alternative to traditional open or endoscopic surgery

Patients answered three questionnaires (Quick-Disabilities of the Arm, Shoulder, and Hand [QDASH] and two parts of the Boston Carpal Tunnel Syndrome Questionnaire: symptom severity [BCTSQ-SS] and functional status [BCTSQ-FS] scales) assessing the affected wrist's function and discomfort immediately pre-procedure, 2 weeks post-procedure, and at least one year post-procedure. Infographic courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Ultrasound Imaging | September 17, 2020
September 17, 2020 — According to ARRS' American Journal of Roentgenology (AJR),...
News | Artificial Intelligence | September 16, 2020
September 16, 2020 — Konica Minolta Healthcare Americas, Inc.